Enhanced Affinity for 3‑Amino-Chromane-Derived σ1 Receptor Ligands

The σ1 receptor is implicated in regulating a diverse range of physiology and is a target for developing therapies for cancer, pain management, neural degradation, and COVID-19. This report describes 36 phenethylamine-containing 3-amino-chromane ligands, which bind to σ1 with low nM affinities. The...

Full description

Saved in:
Bibliographic Details
Published inACS omega Vol. 5; no. 50; pp. 32724 - 32737
Main Authors Porter, Matthew R, Xiao, Haiyan, Maity, Sanjay, Vail, Nora, Smith, Sylvia B, Topczewski, Joseph J
Format Journal Article
LanguageEnglish
Published American Chemical Society 22.12.2020
Online AccessGet full text

Cover

More Information
Summary:The σ1 receptor is implicated in regulating a diverse range of physiology and is a target for developing therapies for cancer, pain management, neural degradation, and COVID-19. This report describes 36 phenethylamine-containing 3-amino-chromane ligands, which bind to σ1 with low nM affinities. The family consists of 18 distinct compounds and each enantiomer was independently assayed. Three compounds with the greatest affinity bind in the 2 nM K i range (∼8.7 pK i). Furthermore, ligands with the (3R,4R) absolute stereochemistry on the 3-amino-chromane core have a higher affinity and greater σ1 versus TMEM97 selectivity. The most promising ligands were assayed in 661W cells, which did not show significant protective effects.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2470-1343
2470-1343
DOI:10.1021/acsomega.0c05117